5 Best IPO Stocks with Huge Upside Potential
ποΈ Oklo Inc. (NYSE: OKLO) acquired Creative Engineers/CEI on June 30 to integrate specialized expertise in sodium-cooled reactor systems.
π· The acquisition brings approximately 20 engineers and fabricators in-house to accelerate design iterations and reduce execution risks for the Aurora powerhouse technology.
π° CEI is a free cash flow-positive business that will allow Oklo to internalize critical engineering and testing functions.
π AEVEX Corp. (NYSE: AVEX) secured a $17.5 million follow-on contract on July 6 for mission-focused data-driven services supporting US national security objectives.
π AEVEX appointed Murali Krishnan as Chief Growth Officer on June 30, leveraging his two decades of experience in defense technology and national security.
π Kailera Therapeutics Inc. (NASDAQ: KLRA) announced positive topline results from two Phase 3 trials for its oral GLP-1 receptor agonist HRS-7535/KAI-7535 on July 7.
βοΈ In the obesity trial, participants achieved a mean weight loss of up to 10.9% by Week 44 and 11.1% by Week 50 with no observed liver safety signals.
π HawkEye 360 Inc. (NYSE: HAWK) reported record FQ1 2026 financial results with a 116.5% year-over-year revenue increase to $49.8 million and adjusted EBITDA of $7.4 million.
π°οΈ HawkEye 360 completed an IPO in May raising $435.9 million and secured over $100 million in new international contract awards so far in 2026.
π€ WeRide Inc. (NASDAQ: WRD) announced a partnership on June 22 to develop robotaxis for right-hand-drive markets with Geely Farizon and Kwoon Chung Bus Holdings.
π The WeRide initiative aims to launch mass-produced vehicles based on the GXR platform with initial deployments beginning in Hong Kong.
π― WeRide plans to scale its global fleet to 2,600 vehicles by the end of 2026, aligning with China's five-year development plan for intelligent new energy vehicles.
- Oklo Inc. acquired CEI, a free cash flow-positive business, to accelerate design iterations and reduce execution risks for its Aurora powerhouse technology.
- AEVEX Corp. secured a $17.5 million follow-on contract to provide mission-focused services supporting US national security objectives.
- Kailera Therapeutics demonstrated strong efficacy in Phase 3 trials with up to 10.9% mean weight loss by Week 44 and no observed liver safety signals.
- HawkEye 360 reported record Q1 2026 revenue of $49.8 million (up 116.5%) and adjusted EBITDA of $7.4 million (up 92.1%).
- HawkEye 360 raised $435.9 million in its May IPO and secured over $100 million in new international contract awards in 2026.
- WeRide Inc. formed a strategic partnership to develop robotaxis for right-hand-drive markets, targeting a global fleet of 2,600 vehicles by the end of 2026.